ClinicalTrials.Veeva

Menu
P

Preferred Research Partners, Inc. | Little Rock, AR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

AD109
Linaclotide
Atogepant
Vonoprazan
Serdexmethylphenidate
PCN-101
Ubrogepant
Deudomperidone
d-MPH
LY3437943

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 23 total trials

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (E...

Active, not recruiting
Eosinophilic Esophagitis
Procedure: Esophagogastroduodenoscopy
Drug: Placebo oral tablet

The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar diso...

Active, not recruiting
Bipolar Disorder
Drug: JNJ-55308942
Drug: Placebo
Recently updated

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropath...

Enrolling
Diabetic Peripheral Neuropathy
Drug: LY3556050
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Atogepant
Drug: Placebo-Matching Atogepant

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as ev...

Active, not recruiting
Fibrosis, Liver
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: Rencofilstat

Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause.Menopause is part of a natural aging pr...

Enrolling
Sleep Disturbances Associated With Menopause
Other: Placebo
Drug: Elinzanetant

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling
Insomnia
Drug: Daridorexant 10 mg
Drug: Daridorexant 25 mg

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: Placebo
Drug: AD109

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Enrolling
OSA
Drug: Placebo
Drug: AD109

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

AbbVie logo
Apnimed logo
Lilly logo
Phathom Pharmaceuticals logo
Bayer logo
C
C
E
G
H

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems